Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category
Neuroscience Neurology process Growth and Development Neurotrophins

Recombinant human TrkA (mutated G595R + G667C) protein (Active) (ab269071)

Recombinant human TrkA (mutated G595R + G667C) protein (Active) (ab269071)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)

Key features and details

  • Expression system: Baculovirus infected Sf9 cells
  • Purity: > 80% SDS-PAGE
  • Active: Yes
  • Tags: GST tag N-Terminus
  • Suitable for: Functional Studies, SDS-PAGE

You may also be interested in

Product image
Anti-p75 NGF Receptor antibody [NTR/912] - BSA and Azide free (ab212684)
Product image
Recombinant Human TrkB protein (His tag) (ab276193)
Product image
Recombinant Human Midkine protein (ab49848)
Product image
Anti-TrkC antibody (ab227289)

Description

  • Product name

    Recombinant human TrkA (mutated G595R + G667C) protein (Active)
    See all TrkA proteins and peptides
  • Biological activity

    The specific activity of ab269071 was 6.9 nmol/min/mg in a kinase assay using Poly (4:1 Glu, Tyr) synthetic peptide as substrate.

  • Purity

    > 80 % SDS-PAGE.

  • Expression system

    Baculovirus infected Sf9 cells
  • Accession

    P04629
  • Protein length

    Protein fragment
  • Animal free

    No
  • Nature

    Recombinant
    • Species

      Human
    • Molecular weight information

      66 kDa by SDS-PAGE
    • Amino acids

      440 to 796
    • Modifications

      mutated G595R + G667C
    • Tags

      GST tag N-Terminus
    • Additional sequence information

      NM_002529

Preparation and Storage

  • Stability and Storage

    Shipped on Dry Ice. Upon delivery aliquot. Store at -80°C. Avoid freeze / thaw cycle.

    pH: 7.50
    Constituents: 0.79% Tris HCl, 0.87% Sodium chloride, 0.31% Glutathione, 0.003% EDTA, 0.004% DTT, 0.002% PMSF, 25% Glycerol (glycerin, glycerine)

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

Images

  • Functional Studies - Recombinant human TrkA (mutated G595R + G667C) protein (Active) (ab269071)
    Functional Studies - Recombinant human TrkA (mutated G595R + G667C) protein (Active) (ab269071)

    The specific activity of ab269071 was 6.9 nmol/min/mg in a kinase assay using Poly (4:1 Glu, Tyr) synthetic peptide as substrate.

  • SDS-PAGE - Recombinant human TrkA (mutated G595R + G667C) protein (Active) (ab269071)
    SDS-PAGE - Recombinant human TrkA (mutated G595R + G667C) protein (Active) (ab269071)

    SDS-PAGE analysis of ab269071.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

  •  
  • Product image

    Anti-TRP1 antibody [EPR13063] (ab178676)

  •  
  • Product image

    Anti-MMP3 antibody [EP1186Y] (ab52915)

  •  
  • Product image

    Anti-GDF15 antibody [EPR19939] (ab206414)

  •  
  • Product image

    Anti-DAP12 antibody [EPR5173] (ab124834)

  •  
  • Product image

    Anti-NOXA2/p67phox antibody [EPR5065] (ab109523)

  •  
  • Product image

    Rabbit IgG, monoclonal [EPR25A] - Isotype Control (Low endotoxin, Azide free) (ab199376)

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.